Haemonetics
Haemonetics Corporation, commonly referred to as Haemonetics, is a leading global healthcare company headquartered in the United States. Founded in 1971, the company has established itself as a key player in the blood management industry, focusing on innovative solutions for blood collection, processing, and transfusion. With major operational regions across North America, Europe, and Asia, Haemonetics serves hospitals and blood centres worldwide. The company’s core products include blood collection systems, automated blood processing equipment, and software solutions that enhance the efficiency and safety of blood management. Haemonetics is recognised for its commitment to quality and innovation, positioning itself as a trusted partner in the healthcare sector. Notable achievements include a strong market presence and a reputation for advancing transfusion medicine, making Haemonetics a vital contributor to improving patient outcomes globally.
DitchCarbon Score
How does Haemonetics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haemonetics's score of 20 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Haemonetics's reported carbon emissions
In 2022, Haemonetics reported total carbon emissions of approximately 25,718,620 kg CO2e, comprising 5,701,850 kg CO2e from Scope 1 and 19,361,770 kg CO2e from Scope 2 emissions. This marked a slight increase in Scope 1 emissions compared to 2021, where they were about 5,071,360 kg CO2e, while Scope 2 emissions decreased from approximately 21,180,860 kg CO2e in 2021. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. As a result, their current climate commitments remain unclear, and there are no documented strategies for reducing their carbon footprint. Haemonetics, headquartered in the US, continues to navigate the challenges of carbon emissions within the medical technology industry, where sustainability practices are increasingly vital.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 5,168,600 | 0,000,000 | 0,000,000 |
| Scope 2 | 22,983,160 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haemonetics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
